Association of tumor necrosis factor-α gene polymorphisms and coronary artery disease susceptibility: a systematic review and meta-analysis

Huang, Rui; Zhao, Su-Rui; Li, Ya; Liu, Fang; Gong, Yantao; Jun, Xing; Xu, Zhou

doi:10.1186/s12881-020-0952-2

Cited by 15 publications

(14 citation statements)

References 25 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some researchers have reported that TNF-α -308G/A polymorphism is implicated in CAD development [ 37 , 38 ], whereas some others reported no evidence in this context [ 39 ]. It is suggested that the implication of the polymorphism in CAD pathogenesis differs between geographical ethnicities, and there was no significant association of TNF-α -308G/A polymorphism with the development of CAD according to a recent meta-analysis [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

“…There is an SNP (Rs1800629) in the promoter region of the TNF-α (position-308G/A), where allele A at this position ( TNF-α -308A) is suggested to be associated with the higher occurrence of OSA [ 21 ] as well as with the severity of this disorder [ 18 , 22 , 23 , 24 , 25 ]. An association between TNF-α -308A allele and obesity is also reported [ 17 , 21 ], whereas there is no significant association of TNF-α-308G/A polymorphism with CAD according to a recent meta-analysis [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of TNF-α (-308G/A) Gene Polymorphism with Circulating TNF-α Levels and Excessive Daytime Sleepiness in Adults with Coronary Artery Disease and Concomitant Obstructive Sleep Apnea

Behboudi

Thelander

Yazıcı

et al. 2021

JCM

View full text Add to dashboard Cite

Obstructive sleep apnea (OSA) is common in patients with coronary artery disease (CAD), in which inflammatory activity has a crucial role. The manifestation of OSA varies significantly between individuals in clinical cohorts; not all adults with OSA demonstrate the same set of symptoms; i.e., excessive daytime sleepiness (EDS) and/or increased levels of inflammatory biomarkers. The further exploration of the molecular basis of these differences is therefore essential for a better understanding of the OSA phenotypes in cardiac patients. In this current secondary analysis of the Randomized Intervention with Continuous Positive Airway Pressure in CAD and OSA (RICCADSA) trial (Trial Registry: ClinicalTrials.gov; No: NCT 00519597), we aimed to address the association of tumor necrosis factor alpha (TNF-α)-308G/A gene polymorphism with circulating TNF-α levels and EDS among 326 participants. CAD patients with OSA (apnea–hypopnea-index (AHI) ≥ 15 events/h; n = 256) were categorized as having EDS (n = 100) or no-EDS (n = 156) based on the Epworth Sleepiness Scale score with a cut-off of 10. CAD patients with no-OSA (AHI < 5 events/h; n = 70) were included as a control group. The results demonstrated no significant differences regarding the distribution of the TNF-α alleles and genotypes between CAD patients with vs. without OSA. In a multivariate analysis, the oxygen desaturation index and TNF-α genotypes from GG to GA and GA to AA as well as the TNF-α-308A allele carriage were significantly associated with the circulating TNF-α levels. Moreover, the TNF-α-308A allele was associated with a decreased risk for EDS (odds ratio 0.64, 95% confidence interval 0.41–0.99; p = 0.043) independent of age, sex, obesity, OSA severity and the circulating TNF-α levels. We conclude that the TNF-α-308A allele appears to modulate circulatory TNF-α levels and mitigate EDS in adults with CAD and concomitant OSA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association of TNF-α (-308G/A) Gene Polymorphism with Circulating TNF-α Levels and Excessive Daytime Sleepiness in Adults with Coronary Artery Disease and Concomitant Obstructive Sleep Apnea

Behboudi

Thelander

Yazıcı

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Therapeutic targeting of TNF has shown benefit in the prevention of atherosclerosis in RA (Del Porto et al 2007), which might also be the case in psoriasis (Sattar et al 2007). Interestingly, a recent meta-analysis that includes 7,697 coronary artery disease (CAD) patients and 9,655 control patients has investigated the association of TNF gene polymorphisms and CAD susceptibility (Huang et al 2020). The authors concluded that there was no association of TNF 308G/A, 857C/T, 863C/A, and 1031 T polymorphisms with CAD susceptibility.…”

Section: Golimumabmentioning

confidence: 99%

Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis

Deroissart

Porsch

Köller

et al. 2021

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Hypercholesterolemia is a major risk factor in atherosclerosis development and lipid-lowering drugs (i.e., statins) remain the treatment of choice. Despite effective reduction of LDL cholesterol in patients, a residual cardiovascular risk persists in some individuals, highlighting the need for further therapeutic intervention. Recently, the CANTOS trial paved the way toward the development of specific therapies targeting inflammation, a key feature in atherosclerosis progression. The pre-existence of multiple drugs modulating both innate and adaptive immune responses has significantly accelerated the number of translational studies applying these drugs to atherosclerosis. Additional preclinical research has led to the discovery of new therapeutic targets, offering promising perspectives for the treatment and prevention of atherosclerosis. Currently, both drugs with selective targeting and broad unspecific anti-inflammatory effects have been tested. In this chapter, we aim to give an overview of current advances in immunomodulatory treatment approaches for atherosclerotic cardiovascular diseases.

show abstract

“…TNF-α, which has been significantly associated to severe cases of COVID-19, has been studied as a driver of vascular dysfunction, atherosclerosis, and heart failure [ 127 ].…”

Section: Cardiovascular Microenvironment: a Focus On Cytokine Stormentioning

confidence: 99%

SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients

Quagliariello

Bonelli

Caronna

et al. 2020

Cancers

View full text Add to dashboard Cite

The coronavirus disease-2019 (COVID-19) is a highly transmissible viral illness caused by SARS-CoV-2, which has been defined by the World Health Organization as a pandemic, considering its remarkable transmission speed worldwide. SARS-CoV-2 interacts with angiotensin-converting enzyme 2 and TMPRSS2, which is a serine protease both expressed in lungs, the gastro-intestinal tract, and cardiac myocytes. Patients with COVID-19 experienced adverse cardiac events (hypertension, venous thromboembolism, arrhythmia, myocardial injury, fulminant myocarditis), and patients with previous cardiovascular disease have a higher risk of death. Cancer patients are extremely vulnerable with a high risk of viral infection and more negative prognosis than healthy people, and the magnitude of effects depends on the type of cancer, recent chemotherapy, radiotherapy, or surgery and other concomitant comorbidities (diabetes, cardiovascular diseases, metabolic syndrome). Patients with active cancer or those treated with cardiotoxic therapies may have heart damages exacerbated by SARS-CoV-2 infection than non-cancer patients. We highlight the cardiovascular side effects of COVID-19 focusing on the main outcomes in cancer patients in updated perspective and retrospective studies. We focus on the main cardio-metabolic risk factors in non-cancer and cancer patients and provide recommendations aimed to reduce cardiovascular events, morbidity, and mortality.

show abstract

Association of tumor necrosis factor-α gene polymorphisms and coronary artery disease susceptibility: a systematic review and meta-analysis

Cited by 15 publications

References 25 publications

Association of TNF-α (-308G/A) Gene Polymorphism with Circulating TNF-α Levels and Excessive Daytime Sleepiness in Adults with Coronary Artery Disease and Concomitant Obstructive Sleep Apnea

Association of TNF-α (-308G/A) Gene Polymorphism with Circulating TNF-α Levels and Excessive Daytime Sleepiness in Adults with Coronary Artery Disease and Concomitant Obstructive Sleep Apnea

Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis

SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients

Contact Info

Product

Resources

About